Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06842498 · ClinicalTrials.gov registry record · Phase 2
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
A Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Kyntra Bio.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
- 15
- Study locations
NCT06842498: Recruiting Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Kyntra Bio.
NCT06842498 is a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer that is actively recruiting participants, run by Kyntra Bio. The registered enrollment target is 75 participants, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (62% lower). The trial reports 15 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06842498, a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, is actively recruiting participants, sponsored by Kyntra Bio.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC who have progressed following treatment with one prior second-generation androgen receptor signaling inhibitor (ARSI) in any setting and no prior taxane therapy in the mCRPC setting.
Conditions Studied
Interventions
- DRUG FG-3246
Study Locations (15)
California
- UCLA Clark Urology Center - Los Angeles
- University of California San Francisco - San Francisco
Florida
- Bioresearch Partner - Aventura
- Bioresearch Partner - Hialeah
North Carolina
- UNC Hospitals, The University of North Carolina at Chapel Hill - Chapel Hill
- Duke University Medical Center - Duke Cancer Center - Durham
Texas
- University of Texas Southwestern Medical Center - Dallas
- Oncology Consultants - Houston
Arizona
- The University of Arizona Cancer Center - North Campus - Tucson
Georgia
- Winship Cancer Institute, Emory University - Atlanta
New Mexico
- New Mexico Oncology Hematology Consultants, Ltd. - Albuquerque
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2026-02-22 |
| Est. Completion | 2028-03-31 |
| Phase | Phase 2 |
What NCT06842498 shows while recruiting
NCT06842498 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which FG-3246 is the first listed.
NCT06842498 lists 15 locations in 11 states (California, Florida, North Carolina).
Frequently Asked Questions
What is clinical trial NCT06842498 about?
NCT06842498 is a clinical study titled "A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)". The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC who have progressed following treatment with one prior second...
What is the current status of trial NCT06842498?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2026-02-22. Estimated completion is 2028-03-31.
What conditions does trial NCT06842498 study?
This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.
What interventions are being tested in trial NCT06842498?
The interventions under investigation include: FG-3246 (DRUG).
Who is sponsoring clinical trial NCT06842498?
This trial is sponsored by Kyntra Bio, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06842498 being conducted?
This trial has 15 study locations across Arizona, California, Florida, Georgia, New Mexico. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Castration-Resistant Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06842498's enrollment target sits among peer trials
75 33rd of 69 higher than 36 of 69 other Metastatic Castration-Resistant Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Castration-Resistant Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
RECRUITING · Phase 2
-
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 2
-
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 2
-
Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
RECRUITING · Phase 2
-
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
RECRUITING · Phase 2
-
Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI